enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN) was the target of a large drop in short interest in December. As of December 15th, there was short interest totalling 50,600 shares, a drop of 93.4% from the November 30th total of 768,300 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily volume of 207,100 shares, the days-to-cover ratio is currently 0.2 days.

Insider Activity

In other enGene news, major shareholder Growth Opportunities F. Forbion bought 5,997 shares of the firm’s stock in a transaction that occurred on Friday, October 4th. The stock was purchased at an average price of $6.54 per share, for a total transaction of $39,220.38. Following the completion of the purchase, the insider now directly owns 2,457,989 shares in the company, valued at $16,075,248.06. This trade represents a 0.24 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have bought 369,326 shares of company stock worth $2,345,518. 13.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Wolverine Asset Management LLC acquired a new position in shares of enGene during the 3rd quarter worth $37,000. Point72 Asset Management L.P. boosted its holdings in enGene by 1,410.3% during the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after buying an additional 619,100 shares in the last quarter. SR One Capital Management LP acquired a new position in enGene during the second quarter worth about $4,715,000. Franklin Resources Inc. grew its position in enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after buying an additional 389,918 shares during the period. Finally, Logos Global Management LP lifted its position in shares of enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after acquiring an additional 400,000 shares during the period. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Stock Performance

Shares of enGene stock traded up $0.28 on Friday, reaching $6.42. 67,687 shares of the stock were exchanged, compared to its average volume of 117,836. The firm has a market capitalization of $283.87 million, a PE ratio of -11.07 and a beta of -0.78. enGene has a 1-year low of $4.42 and a 1-year high of $18.40. The business has a fifty day moving average price of $7.89 and a two-hundred day moving average price of $7.73. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN) last released its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.06. As a group, research analysts anticipate that enGene will post -1.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ENGN shares. Citizens Jmp upgraded enGene to a “strong-buy” rating in a research report on Monday, November 18th. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price objective on shares of enGene in a research note on Monday, December 23rd. Raymond James assumed coverage on shares of enGene in a research report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 target price on the stock. HC Wainwright assumed coverage on shares of enGene in a research report on Monday, December 23rd. They issued a “buy” rating and a $25.00 price target for the company. Finally, Morgan Stanley reissued an “overweight” rating and set a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, enGene currently has an average rating of “Buy” and an average target price of $29.78.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.